135 Stock Chart & Stats
€4.50
€0.00(0.00%)
At close: 4:00 PM EDT
€4.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.45 - €7.48
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€43.73M
Enterprise Value-€4.09
Total Cash (Recent Filing)€54.08M
Total Debt (Recent Filing)€1.95M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Nov 11, 2026EPS Estimate
-0.64Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding9,949,609
10 Day Avg. Volume18
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.64
Price to Sales (P/S)1.53
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€28.47Price Target Upside532.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.13
Revenue Forecast (FY)€1.08M
Bulls Say, Bears Say
Bulls Say
Non-dilutive BARDA FundingThe BARDA contract can materially reduce financing pressure while supporting development of SCY-247 and SCY-770. Funding eligible development costs and maintaining projected cash runway into 2029 could let SCYNEXIS advance important antifungal programs without relying solely on equity or debt.
Conservative Balance SheetVery low leverage gives SCYNEXIS greater financial flexibility as it develops and commercializes antifungal assets. A conservatively funded balance sheet can reduce interest and refinancing pressure, preserve strategic options, and help the company absorb operating volatility over the next several quarters.
Strengthened Biopharma LeadershipAdding experienced biopharma leadership supports the company’s ability to manage capital markets, strategic transactions, regulatory planning, and clinical execution. This expertise is particularly relevant as SCYNEXIS advances rare-disease and antifungal programs through Phase 2 development.
Bears Say
Persistent Unprofitable OperationsSubstantial ongoing losses show that SCYNEXIS has not yet established durable operating profitability. Negative margins limit internally generated funding, increase dependence on financing or partners, and make future earnings power highly dependent on successful development and commercialization of its pipeline.
Continued Cash ConsumptionNegative operating and free cash flow means the business is currently consuming cash rather than self-funding operations and development. Even with improvement from 2024, sustained cash burn can pressure liquidity and constrain investment unless product revenue, partnerships, or external funding expand.
Volatile And Declining Revenue PerformanceThe reversal from strong 2023 performance to sharply lower revenue and losses in 2024, 2025, and TTM indicates limited consistency in the current revenue base. Such volatility makes planning harder and weakens confidence that profitability can be sustained without further product or partnership progress.
SCYNEXIS News
135 FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was €3.44 and its highest was €7.48 in the past 12 months.
What is SCYNEXIS’s market cap?
SCYNEXIS’s market cap is €43.73M.
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Nov 11, 2026 which is in 40 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on Aug 10, 2026. The company reported €0.561 earnings per share for the quarter, beating the consensus estimate of -€0.451 by €1.012.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -0.64.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 9,949,609 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of €0.561 in its last earnings report, beating expectations of -€0.451. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of SCYNEXIS?
Currently, no hedge funds are holding shares in DE:135
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€28.47 (532.74% Upside)
€28.47 (532.74% Upside)
Blogger Sentiment
Bullish
DE:135 Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.96%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
23.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
135 Stock 12 Month Forecast
Average Price Target
€28.47
▲(532.74% Upside)
Technical Analysis
Rockwell Med
―
TherapeuticsMD
―
Aytu BioScience
―
Cumberland Pharmaceuticals
―
IM Cannabis Corp
―